Genmab chief on sclerosis drug launch: Novartis prioritizes us

While Genmab's partner Novartis can start launching sclerosis drug Kesimpta in Europe after receiving EU authorization, the process is well underway in the US – and it's going well, according to CEO Jan van de Winkel.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

On Tuesday, the EU Commission approved the drug Kesimpta, which was developed by Genmab, as a treatment for sclerosis.

Thus, Genmab's partner Novartis, which currently has the rights to the drug, can start launching the drug in Europe. Hopefully, this will pan out as well as it has in the US, where the drug was approved in late August last year.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs